<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref024">
 <label>24</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Zeuzem</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Foster</surname>
   <given-names>GR</given-names>
  </name>, 
  <name>
   <surname>Wang</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Asatryan</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Gane</surname>
   <given-names>E</given-names>
  </name>, 
  <name>
   <surname>Feld</surname>
   <given-names>JJ</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection</article-title>. 
  <source>N Engl J Med</source>. 
  <year>2018</year> 25;
  <volume>378</volume>(
  <issue>4</issue>):
  <fpage>354</fpage>â€“
  <lpage>69</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1702417</pub-id>
  <?supplied-pmid 29365309?>
  <pub-id pub-id-type="pmid">29365309</pub-id>
 </mixed-citation>
</ref>
